Research progress of pomalidomide in the treatment of relapsed refractory multiple myeloma
10.3760/cma.j.issn.1009-9921.2014.03.017
- VernacularTitle:泊马度胺治疗难治复发性多发性骨髓瘤的研究进展
- Author:
Songlin CHU
- Publication Type:Journal Article
- Keywords:
Pomalidomide;
Multiple myeloma;
Immunomodulatory drugs
- From:
Journal of Leukemia & Lymphoma
2014;23(3):179-181
- CountryChina
- Language:Chinese
-
Abstract:
Pomalidomide,which represents a new generation of immunomodulatory drugs (IMiD),has brought a major shift in therapeutic paradigm in treating relapsed and refractory multiple myeloma (RRMM).Considering its encouraging effectiveness,the U.S.Food and Drug Administration (FDA) approved its usage to treat patients who fail to respond to at least two prior therapies,including lenalidomide and bortezomib,and whose disease progressed within 60 days of the last treatment.This review summarizes the mechanisms of action and clinical activity of pomalidomide in treating RRMM.
